Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Apr;35(4):544-556.
doi: 10.1111/jgh.14905. Epub 2019 Nov 7.

Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta-analysis

Affiliations
Meta-Analysis

Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta-analysis

Niandi Tan et al. J Gastroenterol Hepatol. 2020 Apr.

Abstract

Background and aims: The efficacy of herbal medicines (HMs) for functional gastrointestinal disorders (FGIDs) including irritable bowel syndrome (IBS), functional dyspepsia (FD) and functional constipation (FC) is controversial. A systematic review with meta-analysis was conducted to determine their effectiveness for FGIDs.

Methods: We searched the following electronic databases till July 2019 with English language restriction: The Cochrane Library, EMBASE and PUBMED. Randomized double-blind controlled trials of HMs compared with placebo or conventional pharmacological drugs for adult FGIDs patients were included.

Results: In total, 49 trials involving 7396 participants with FGIDs were included. The risk of bias was low in 9, unclear in 36, and high in 4 trials. More than 33 different herbal formulae were tested. HMs demonstrated statistically significant benefits for symptom improvement compared with placebo in 46 trials (RR = 1.67, 95% CI 1.48-1.88). When compared with conventional pharmacological therapy in 5 trials, HMs were found to be non-inferior (RR = 1.10, 95% CI 1.03-1.18). The number of trials with regards to FD, IBS and FC were 19, 23 and 7 respectively. Subgroup analysis found that HMs were better than placebo in alleviating symptoms for FD (RR = 1.50, 95% CI 1.32-1.69), IBS (RR = 1.62, 95% CI 1.32-1.97) and FC (RR = 3.83, 95% CI 2.26-6.50). HMs tended to have more patients with adverse events than placebo, but similar to conventional pharmacological drugs.

Conclusions: Our findings provide a positive signal for HMs as a potentially well-tolerated and effective treatment for FGIDs, deserving further examination in high-quality trials.

Keywords: Functional constipation; Functional dyspepsia; Functional gastrointestinal disorders; Herbal medicine; Irritable bowel syndrome.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology 2016; 150: 1257-1261.
    1. Oshima T, Miwa H. Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World. J. Neurogastroenterol. Motil. 2015; 21: 320-329.
    1. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Aliment. Pharmacol. Ther. 2013; 38: 170-177.
    1. Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment. Pharmacol. Ther. 2019; 49: 1134-1172.
    1. Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut 2006; 55: 593-596.

MeSH terms

Substances

LinkOut - more resources